142 related articles for article (PubMed ID: 32288909)
1. Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis.
Borja-Cabrera GP; Santos FB; Picillo E; Gravino AE; Manna L; Palatnik-de-Sousa CB
Procedia Vaccinol; 2009; 1(1):104-109. PubMed ID: 32288909
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside Hydrolase NH 36: A Vital Enzyme for the
Palatnik-de-Sousa CB
Front Immunol; 2019; 10():813. PubMed ID: 31040850
[TBL] [Abstract][Full Text] [Related]
3. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
[TBL] [Abstract][Full Text] [Related]
4. Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains.
Nico D; Gomes DC; Alves-Silva MV; Freitas EO; Morrot A; Bahia D; Palatnik M; Rodrigues MM; Palatnik-de-Sousa CB
Front Immunol; 2014; 5():189. PubMed ID: 24822054
[TBL] [Abstract][Full Text] [Related]
5. NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.
Nico D; Martins Almeida F; Maria Motta J; Soares Dos Santos Cardoso F; Freire-de-Lima CG; Freire-de-Lima L; de Luca PM; Maria Blanco Martinez A; Morrot A; Palatnik-de-Sousa CB
Front Immunol; 2018; 9():967. PubMed ID: 29867949
[TBL] [Abstract][Full Text] [Related]
6. The F1F3 Recombinant Chimera of
Alves-Silva MV; Nico D; de Luca PM; Palatnik de-Sousa CB
Front Immunol; 2019; 10():724. PubMed ID: 31024556
[No Abstract] [Full Text] [Related]
7. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine.
Santos FN; Borja-Cabrera GP; Miyashiro LM; Grechi J; Reis AB; Moreira MA; Martins Filho OA; Luvizotto MC; Menz I; Pessôa LM; Gonçalves PR; Palatnik M; Palatnik-de-Sousa CB
Vaccine; 2007 Aug; 25(33):6176-90. PubMed ID: 17630055
[TBL] [Abstract][Full Text] [Related]
8. F1 Domain of the
Carrillo E; Fernandez L; Ibarra-Meneses AV; Santos MLB; Nico D; de Luca PM; Correa CB; de Almeida RP; Moreno J; Palatnik-de-Sousa CB
Front Immunol; 2017; 8():750. PubMed ID: 28747911
[TBL] [Abstract][Full Text] [Related]
9. A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the
Alves-Silva MV; Nico D; Morrot A; Palatnik M; Palatnik-de-Sousa CB
Front Immunol; 2017; 8():100. PubMed ID: 28280494
[TBL] [Abstract][Full Text] [Related]
10.
Barbosa Santos ML; Nico D; de Oliveira FA; Barreto AS; Palatnik-de-Sousa I; Carrillo E; Moreno J; de Luca PM; Morrot A; Rosa DS; Palatnik M; Bani-Corrêa C; de Almeida RP; Palatnik-de-Sousa CB
Front Immunol; 2017; 8():227. PubMed ID: 28321221
[TBL] [Abstract][Full Text] [Related]
11. Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.
Nico D; Gomes DC; Palatnik-de-Sousa I; Morrot A; Palatnik M; Palatnik-de-Sousa CB
Front Immunol; 2014; 5():273. PubMed ID: 24966857
[TBL] [Abstract][Full Text] [Related]
12. Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response.
Nico D; Claser C; Borja-Cabrera GP; Travassos LR; Palatnik M; Soares IS; Rodrigues MM; Palatnik-de-Sousa CB
PLoS Negl Trop Dis; 2010 Nov; 4(11):e866. PubMed ID: 21085470
[TBL] [Abstract][Full Text] [Related]
13. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
Saraiva EM; de Figueiredo Barbosa A; Santos FN; Borja-Cabrera GP; Nico D; Souza LO; de Oliveira Mendes-Aguiar C; de Souza EP; Fampa P; Parra LE; Menz I; Dias JG; de Oliveira SM; Palatnik-de-Sousa CB
Vaccine; 2006 Mar; 24(13):2423-31. PubMed ID: 16386824
[TBL] [Abstract][Full Text] [Related]
14. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.
Borja-Cabrera GP; Cruz Mendes A; Paraguai de Souza E; Hashimoto Okada LY; de A Trivellato FA; Kawasaki JK; Costa AC; Reis AB; Genaro O; Batista LM; Palatnik M; Palatnik-de-Sousa CB
Vaccine; 2004 Jun; 22(17-18):2234-43. PubMed ID: 15149782
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
[TBL] [Abstract][Full Text] [Related]
16. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
[TBL] [Abstract][Full Text] [Related]
17. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
[TBL] [Abstract][Full Text] [Related]
18. FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.
Palatnik-de-Sousa CB; Barbosa Ade F; Oliveira SM; Nico D; Bernardo RR; Santos WR; Rodrigues MM; Soares I; Borja-Cabrera GP
Expert Rev Vaccines; 2008 Aug; 7(6):833-51. PubMed ID: 18665780
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
20. Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated Leishmania donovani centrin deleted parasites (LdCen-/-).
Viana KF; Fiuza JA; Gannavaram S; Dey R; Selvapandiyan A; Bartholomeu DC; da Silveira-Lemos D; Bueno LL; Dutra WO; Fujiwara RT; Nakhasi HL; Giunchetti RC
Parasit Vectors; 2016 Apr; 9():250. PubMed ID: 27136900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
